{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:31:08Z","timestamp":1793579468541,"version":"4.5.0"},"reference-count":99,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>This review article represents a collaborative effort across continents, bringing together the latest developments in neuro-ophthalmology with a focus on innovative diagnostic and therapeutic modalities that are shaping the future of the field. Among the most significant advancements is the rise of optical coherence tomography (OCT), now recognized as an indispensable tool in neuro-ophthalmological research, providing unparalleled insights into optic nerve and central nervous system pathologies. Gene therapy, particularly for conditions such as Leber's hereditary optic neuropathy, marks a new frontier in personalized medicine, offering hope for previously untreatable conditions. The article also examines the transformative role of telemedicine and artificial intelligence (AI) in clinical practice, which are revolutionizing patient care and enhancing diagnostic precision. Furthermore, it highlights the impact of novel serological biomarkers on the understanding and management of immune-mediated optic neuritis, and discusses the introduction of new therapeutic agents like Tocilizumab and Teprotumumab, which are redefining treatment paradigms. Collectively, these advancements reflect the profound influence of modern medicine on neuro-ophthalmology, paving the way for improved patient outcomes and fostering new avenues for research and clinical practice.<\/jats:p>","DOI":"10.4103\/ijo.ijo_594_24","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T20:06:57Z","timestamp":1735589217000},"page":"1544-1559","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Recent advances in neuro-ophthalmology"],"prefix":"10.4103","volume":"72","author":[{"given":"Shikha T","family":"Bassi","sequence":"first","affiliation":[{"name":"Neuro Ophthalmology Services, Sankara Nethralaya, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J","family":"Newman","sequence":"additional","affiliation":[{"name":"Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota (MN), USA"},{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanthaya Yui","family":"Tisavipat","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P","family":"Mollan","sequence":"additional","affiliation":[{"name":"Birmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom (UK)"},{"name":"Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E","family":"Moss","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Milea","sequence":"additional","affiliation":[{"name":"Visual Neuroscience Group, Singapore Eye Research Institute and Duke NUS, Medical School, Singapore"},{"name":"Rothschild Foundation Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"R1-20260425","doi-asserted-by":"crossref","first-page":"79.","DOI":"10.1038\/s43586-022-00162-2","article-title":"Optical coherence tomography","volume":"2","author":"Bouma","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"R2-20260425","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1167\/iovs.14-14960","article-title":"Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: Quality control, comparisons, and variability","volume":"55","author":"Auinger","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-20260425","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/NRL.0000000000000528","article-title":"The relationship between lumbar puncture opening pressure and retinal nerve fiber layer thickness in the diagnosis of idiopathic intracranial hypertension: Is a lumbar puncture always necessary?","volume":"29","author":"Kaya Tutar","year":"2024","journal-title":"Neurologist"},{"key":"R4-20260425","first-page":"672","article-title":"Optical coherence tomography in papilledema: A probe into the intracranial pressure correlation","volume":"72","author":"Bassi","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R5-20260425","first-page":"1264","article-title":"Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension","volume":"138","author":"Vijay","year":"2020","journal-title":"JAMAOphthalmol"},{"key":"R6-20260425","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1167\/iovs.16-21089","article-title":"Peripapillary retinal pigment epithelium layer shape changes from acetazolamide treatment in the idiopathic intracranial hypertension treatment trial","volume":"58","author":"Wang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20260425","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WNO.0000000000001945","article-title":"Early detection of optic nerve changes on optical coherence tomography using deep learning for risk-stratification of papilledema and glaucoma","volume":"44","author":"Li","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"R8-20260425","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.4103\/IJO.IJO_3146_22","article-title":"Understanding pseudopapilledema on spectral domain optical coherence tomography","volume":"71","author":"Bassi","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R9-20260425","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41433-023-02489-w","article-title":"Prevalence of peripapillary hyperreflective ovoid mass-like structures (PHOMS) in suspected papilloedema in children","volume":"37","author":"Pratt","year":"2023","journal-title":"Eye (Lond)"},{"key":"R10-20260425","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01658107.2022.2116458","article-title":"Upper limit of retinal nerve fibre layer thickness in patients with pseudopapilloedema","volume":"46","author":"Pramil","year":"2022","journal-title":"Neuroophthalmology"},{"key":"R11-20260425","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201350","article-title":"Discriminating between papilledema and optic disc drusen using 3D structural analysis of the optic nerve head","volume":"100","author":"Girard","year":"2023","journal-title":"Neurology"},{"key":"R12-20260425","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WNO.0000000000000585","article-title":"The optic disc drusen studies consortium recommendations for diagnosis of optic disc drusen using optical coherence tomography","volume":"38","author":"Malmqvist","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"R13-20260425","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ajo.2020.05.034","article-title":"Bruch\u2019s membrane opening minimum rim width provides objective differentiation between glaucoma and nonglaucomatous optic neuropathies","volume":"218","author":"Leaney","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R14-20260425","first-page":"2520","article-title":"Correlation between morphological and functional retinal impairment in multiple sclerosis patients","volume":"40","author":"Parisi","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R15-20260425","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1177\/13524585231198760","article-title":"Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis","volume":"29","author":"Cerd\u00e1-Fuertes","year":"2023","journal-title":"Mult Scler"},{"key":"R16-20260425","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1212\/WNL.0000000000207507","article-title":"Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for multiple sclerosis","volume":"101","author":"Bsteh","year":"2023","journal-title":"Neurology"},{"key":"R17-20260425","doi-asserted-by":"crossref","first-page":"e1068.","DOI":"10.1212\/NXI.0000000000001068","article-title":"Retinal optical coherence tomography in neuromyelitis optica","volume":"8","author":"Oertel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R18-20260425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/EB.S235238","article-title":"Optical coherence tomography in patients with Alzheimer\u2019s disease: What can it tell us?","volume":"13","author":"Song","year":"2021","journal-title":"Eye Brain"},{"key":"R19-20260425","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1007\/s10072-023-07256-z","article-title":"Correlation between serum biomarkers, brain volume, and retinal neuronal loss in early-onset Alzheimer\u2019s disease","volume":"45","author":"Zhang","year":"2024","journal-title":"Neurol Sci"},{"key":"R20-20260425","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3233\/ADR-230042","article-title":"A Systematic review on retinal biomarkers to diagnose dementia from OCT\/OCTA images","volume":"7","author":"Ibrahim","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"R21-20260425","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.4103\/IJO.IJO_2537_22","article-title":"Evaluation of optical coherence tomography angiography changes in nonarteritic anterior ischemic optic neuropathy","volume":"71","author":"Phuljhele","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R22-20260425","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.omtn.2023.05.014","article-title":"Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy","volume":"32","author":"Srivastava","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"R23-20260425","doi-asserted-by":"crossref","first-page":"1119724.","DOI":"10.3389\/fnins.2023.1119724","article-title":"Comparison of different gene-therapy methods to treat Leber hereditary optic neuropathy in a mouse model","volume":"17","author":"Velmurugan","year":"2023","journal-title":"Front Neurosci"},{"key":"R24-20260425","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/IIO.0000000000000364","article-title":"Gene therapies for the treatment of Leber hereditary optic neuropathy","volume":"61","author":"Sahel","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"R25-20260425","doi-asserted-by":"crossref","first-page":"21587.","DOI":"10.1038\/srep21587","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy","volume":"6","author":"Wan","year":"2016","journal-title":"Sci Rep"},{"key":"R26-20260425","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"key":"R27-20260425","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ophtha.2020.02.023","article-title":"Seven-year follow-up of gene therapy for Leber\u2019s hereditary optic neuropathy","volume":"127","author":"Yuan","year":"2020","journal-title":"Ophthalmology"},{"key":"R28-20260425","first-page":"558","article-title":"First China international gene therapy study in Leber hereditary optic neuropathy","volume":"28","author":"Xiao","year":"2020","journal-title":"Mol Ther"},{"key":"R29-20260425","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1111\/aos.14379","article-title":"Factors associated with rapid improvement in visual acuity in patients with leber\u2019s hereditary optic neuropathy after gene therapy","volume":"98","author":"Liu","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R30-20260425","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for Leber hereditary optic neuropathy: Initial results","volume":"123","author":"Feuer","year":"2017","journal-title":"Ophthalmology"},{"key":"R31-20260425","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: Low- and medium-dose visual results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"key":"R32-20260425","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2022.02.023","article-title":"Leber hereditary optic neuropathy gene therapy: Adverse events and visual acuity results of all patient groups","volume":"241","author":"Lam","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R33-20260425","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","article-title":"Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: The REVEAL study","volume":"35","author":"Vignal-Clermont","year":"2021","journal-title":"BioDrugs"},{"key":"R34-20260425","doi-asserted-by":"crossref","first-page":"eaaz7423","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Trans Med"},{"key":"R35-20260425","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","article-title":"Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset","volume":"128","author":"Newman","year":"2021","journal-title":"Ophthalmology"},{"key":"R36-20260425","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","article-title":"Long-term follow-up after unilateral intravitreal gene therapy for Leber hereditary optic neuropathy: The RESTORE study","volume":"41","author":"Biousse","year":"2021","journal-title":"J Neuro-Ophthalmol"},{"key":"R37-20260425","doi-asserted-by":"crossref","first-page":"662838.","DOI":"10.3389\/fneur.2021.662838","article-title":"Intravitreal gene therapy vs. natural history in patients with leber hereditary optic neuropathy carrying the m.11778G>AND4 mutation: Systematic review and indirect comparison","volume":"12","author":"Newman","year":"2021","journal-title":"Front Neurol"},{"key":"R38-20260425","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/brain\/awac421","article-title":"Randomized trial of bilateral gene therapy injection form.11778G>A MT-ND4 Leber optic neuropathy","volume":"146","author":"Newman","year":"2023","journal-title":"Brain"},{"key":"R39-20260425","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40123-022-00611-x","article-title":"Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in patients with leber hereditary optic neuropathy carrying the m.11778G>A MT-ND4 mutation","volume":"12","author":"Carelli","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R40-20260425","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2022.11.026","article-title":"Safety of lenadogene nolparvovec gene therapy over 5 years in 189 patients with Leber hereditary optic neuropathy","volume":"249","author":"Vignal-Clermont","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R41-20260425","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/WNO.0000000000001045","article-title":"Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G&gt; A (MTND4) mitochondrial DNA mutation","volume":"40","author":"Newman","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"R42-20260425","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.omtm.2021.09.013","article-title":"Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates","volume":"23","author":"Calkins","year":"2021","journal-title":"J Mol Ther Methods Clin Dev"},{"key":"R43-20260425","article-title":"Bilateral ocular post-mortem analyses in a patient with Leber hereditary optic neuropathy treated with unilateral AAV2 gene therapy","author":"Carelli","year":"2023","journal-title":"11th European Meeting on Mitochondrial Pathology (EUROMIT) (Platform Presentation),Bologna, Italy, June"},{"key":"R44-20260425","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","article-title":"International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy","volume":"37","author":"Carelli","year":"2017","journal-title":"J Neuro-Ophthalmol"},{"key":"R45-20260425","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMcibr2002015","article-title":"Mitochondrial replacement in the clinic","volume":"382","author":"Chinnery","year":"2020","journal-title":"N Engl J Med"},{"key":"R46-20260425","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R47-20260425","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/13524585211011450","article-title":"Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder","volume":"28","author":"Tajfirouz","year":"2022","journal-title":"Mult Scler"},{"key":"R48-20260425","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2015.05.013","article-title":"Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis","volume":"355","author":"Mealy","year":"2015","journal-title":"J Neurol Sci"},{"key":"R49-20260425","doi-asserted-by":"crossref","first-page":"e572.","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurology-Neuroimmunol Neuroinflam"},{"key":"R50-20260425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: An International multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R51-20260425","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"R52-20260425","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R53-20260425","doi-asserted-by":"crossref","first-page":"104237.","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R54-20260425","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1212\/WNL.0000000000013087","article-title":"Glial fibrillary acidic protein autoimmunity: A Frenchcohort study","volume":"98","author":"Gravier-Dumonceau","year":"2022","journal-title":"Neurology"},{"key":"R55-20260425","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as a biomarker of autoimmune astrocytopathy: Analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"key":"R56-20260425","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/WNO.0000000000000593","article-title":"Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis","volume":"38","author":"Chen","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"R57-20260425","doi-asserted-by":"crossref","first-page":"e1014.","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R58-20260425","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ophtha.2019.09.012","article-title":"Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema","volume":"127","author":"Cohen","year":"2020","journal-title":"Ophthalmology"},{"key":"R59-20260425","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: An update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R60-20260425","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody-positive myasthenia gravis: A multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"R61-20260425","doi-asserted-by":"crossref","first-page":"577895.","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"J Neuroimmunol"},{"key":"R62-20260425","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WNO.0000000000001005","article-title":"Neuro-ophthalmic features of autoimmune encephalitides","volume":"40","author":"Bohm","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"R63-20260425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R64-20260425","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"R65-20260425","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"R66-20260425","doi-asserted-by":"crossref","first-page":"3331024231197118.","DOI":"10.1177\/03331024231197118","article-title":"Guidelines of the International Headache Society for controlled clinical trials in idiopathic intracranial hypertension","volume":"43","author":"Mollan","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"R67-20260425","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s10194-020-01093-7","article-title":"European Headache Federation recommendations for neurologists managing giant cell arteritis","volume":"21","author":"Mollan","year":"2020","journal-title":"J Headache Pain"},{"key":"R69-20260425","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13543784.2021.2010704","article-title":"Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis","volume":"30","author":"Chen","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"R70-20260425","doi-asserted-by":"crossref","first-page":"1166490.","DOI":"10.3389\/fneur.2023.1166490","article-title":"Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis","volume":"14","author":"Aungsumart","year":"2023","journal-title":"Front Neurol"},{"key":"R71-20260425","doi-asserted-by":"crossref","first-page":"104571.","DOI":"10.1016\/j.msard.2023.104571","article-title":"Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"72","author":"Chang","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R72-20260425","doi-asserted-by":"crossref","first-page":"e220189.","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"R73-20260425","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14737175.2023.2206567","article-title":"Current and emerging diagnostic and management approaches for idiopathic intracranial hypertension","volume":"23","author":"Piccus","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"R74-20260425","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/EJE-22-0108","article-title":"Increased systemic and adipose 11\u03b2-HSD1 activity in idiopathic intracranialhypertension","volume":"187","author":"Westgate","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R75-20260425","doi-asserted-by":"crossref","first-page":"e181.","DOI":"10.2196\/resprot.7806","article-title":"Assessing the efficacy and safety of an 11\u03b2-hydroxysteroid dehydrogenase type 1inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH: DT: Clinical methods and design for a phase II randomized controlled trial","volume":"6","author":"Markey","year":"2017","journal-title":"JMIR Res Protoc"},{"key":"R76-20260425","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/clinem\/dgaa766","article-title":"11\u03b2HSD1 Inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension","volume":"106","author":"Hardy","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R77-20260425","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNO.0000000000001902","article-title":"Common design and data elements reported on idiopathic intracranial hypertension trials: A systematic review","volume":"44","author":"Kobeissi","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"R78-20260425","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension:A randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","journal-title":"Brain"},{"key":"R79-20260425","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WNO.0000000000000582","article-title":"A profile of neuro-ophthalmic practice around the world","volume":"38","author":"Frohman","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"R80-20260425","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1377\/hlthaff.2023.01142","article-title":"The Impact Of Telemedicine On Medicare Utilization, Spending, And Quality,2019\u201322","volume":"43","author":"Nakamoto","year":"2024","journal-title":"Health Aff (Millwood)"},{"key":"R81-20260425","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1357633X20949796","article-title":"Optimising telemedicine in ophthalmology during the COVID-19 pandemic","volume":"28","author":"Patel","year":"2022","journal-title":"J Telemed Telecare"},{"key":"R82-20260425","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/WNO.0000000000001051","article-title":"Survey of telehealth adoption by neuro-ophthalmologists during the COVID-19 pandemic: Benefits, barriers, and utility","volume":"40","author":"Moss","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"R83-20260425","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/09286586.2023.2180807","article-title":"Evolution of Disparities in Outpatient Ophthalmic Care at a Tertiary Care Center in California at the beginning of and One Year into the COVID-19 Public Health Emergency","volume":"31","author":"Shen","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"key":"R84-20260425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/WNO.0000000000001195","article-title":"Practical approach to the tele-neuro-ophthalmology and neuro-otology visits: Instructional videos","volume":"41","author":"Calix","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"R85-20260425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WCO.0000000000000880","article-title":"Telemedicine for neuro-ophthalmology: Challenges and opportunities","volume":"34","author":"Liu","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"R86-20260425","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/tmj.2020.0372","article-title":"Teleophthalmology in the era of COVID-19: Characteristics of early adopters at a large academic institution","volume":"27","author":"Aguwa","year":"2021","journal-title":"Telemed J E Health"},{"key":"R87-20260425","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/WNO.0000000000001663","article-title":"Tele-neuro-ophthalmology utilization, availability and attitudes: Update 1 year into the COVID-19 public health emergency","volume":"43","author":"Moss","year":"2023","journal-title":"J Neuroophthalmol"},{"key":"R88-20260425","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajo.2021.07.024","article-title":"Disparities in eye care utilization during the COVID-19 pandemic","volume":"233","author":"Elam","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R89-20260425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ophtha.2021.07.003","article-title":"Socioeconomic and demographic disparities in the use of telemedicine for ophthalmic care during the COVID-19 pandemic","volume":"129","author":"Chen","year":"2022","journal-title":"Ophthalmology"},{"key":"R90-20260425","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaophthalmol.2021.3728","article-title":"Association of patient characteristics with delivery of ophthalmic telemedicine during the COVID-19 pandemic","volume":"139","author":"Aziz","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R91-20260425","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjophthalmol-2020-317683","article-title":"New digital models of care in ophthalmology, during and beyond the COVID-19 pandemic","volume":"106","author":"Tham","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R92-20260425","doi-asserted-by":"crossref","first-page":"88","DOI":"10.47102\/annals-acadmedsg.2022369","article-title":"Through the eyes into the brain, using artificial intelligence","volume":"52","author":"Sathianvichitr","year":"2023","journal-title":"Ann Acad Med Singap"},{"key":"R93-20260425","doi-asserted-by":"crossref","first-page":"e058552.","DOI":"10.1136\/bmjopen-2021-058552","article-title":"AlzEye: Longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK","volume":"12","author":"Wagner","year":"2022","journal-title":"BMJ Open"},{"key":"R94-20260425","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.1016\/S2589-7500(22)00169-8","article-title":"A deep learning model for detection of Alzheimer\u2019s disease based on retinal photographs: A retrospective, multicentre case-control study","volume":"4","author":"Cheung","year":"2022","journal-title":"Lancet Digit Health"},{"key":"R95-20260425","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa1917130","article-title":"Artificial intelligence to detect papilledema from ocular fundus photographs","volume":"382","author":"Milea","year":"2020","journal-title":"N Engl J Med"},{"key":"R96-20260425","article-title":"Human clinicians are outperformed by a deep learning system for identification of optic disc lesions heralding vision- and life-threatening conditions","author":"Vasseneix","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"R97-20260425","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ana.25839","article-title":"Optic disc classification by deep learning versus expert neuro-ophthalmologists","volume":"88","author":"Biousse","year":"2020","journal-title":"Ann Neurol"},{"key":"R98-20260425","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1212\/WNL.0000000000012226","article-title":"Accuracy of a deep learning system for classification of papilledema severity on ocular fundus photographs","volume":"97","author":"Vasseneix","year":"2021","journal-title":"Neurology"},{"key":"R99-20260425","article-title":"Application of a deep learning system to detect papilledema on nonmydriatic ocular fundus photographs in an emergency department","author":"Biousse","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R100-20260425","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/APO.0000000000000512","article-title":"Artificial intelligence meets neuro-ophthalmology","volume":"11","author":"Leong","year":"2022","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_594_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:41:07Z","timestamp":1787773267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_594_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_594_24","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"2024-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}